What is HC Wainwright's Estimate for ONCY FY2027 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Research analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of Oncolytics Biotech in a report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.08) per share for the year, up from their prior estimate of ($0.09). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech's FY2028 earnings at $0.39 EPS.

Several other analysts also recently issued reports on the stock. Maxim Group lowered their price objective on shares of Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Royal Bank of Canada lowered their price objective on shares of Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday, March 10th. Three research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $4.00.

Oncolytics Biotech Stock Performance

ONCY traded up $0.00 on Thursday, reaching $0.63. 118,147 shares of the company's stock were exchanged, compared to its average volume of 1,288,895. The company's 50 day moving average is $0.75 and its 200-day moving average is $0.92. The company has a market cap of $53.44 million, a price-to-earnings ratio of -2.31 and a beta of 1.18. Oncolytics Biotech has a twelve month low of $0.58 and a twelve month high of $1.53.

Remove Ads

Hedge Funds Weigh In On Oncolytics Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech during the 4th quarter valued at approximately $27,000. National Bank of Canada FI boosted its stake in shares of Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock valued at $60,000 after buying an additional 42,955 shares during the last quarter. Geode Capital Management LLC lifted its stake in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock worth $61,000 after purchasing an additional 24,997 shares during the last quarter. Virtu Financial LLC bought a new position in Oncolytics Biotech during the fourth quarter worth $90,000. Finally, International Assets Investment Management LLC lifted its stake in Oncolytics Biotech by 15.0% during the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock worth $186,000 after purchasing an additional 26,069 shares during the last quarter. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.